All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

CAR-T 2023

Feb 10, 2023

11 Feb 2023

CONGRESS | #CART23 @MireiaUribe @hospitalclinic shares data suggesting an association between gut microbiota composition and clinical outcome of pts treated with BCMA-directed CAR-T. Combining multiple data sources they have created a predictive model with high accuracy. #mmsm

View on

11 Feb 2023

CONGRESS | #CART23
Gaurav Narula presents access to CAR-T on a global scale – India. Many treatment challenges exist in this region including patient volume, financial burden, malnutrition and patient tracking. Key clinical trials are ongoing. #mmsm #medicalcongress

View on

11 Feb 2023

CONGRESS | #CART23
Kevin Hay @bccancerfdn presents access to CAR-T on a global scale – Canada. While Canada represents global leader in CAR-T cell therapy, access is to treatment is still limited in some areas due to geographical distribution and landscape challenges. #mmsm

View on

11 Feb 2023

CONGRESS | #CART23
Candice Hendricks, @UPTuks presents access to CAR-T on a global scale – South Africa. Currently, there is no patient access to CAR-T products for patients in SA. However progress is being made, with early clinical trials expected to start in 2023. #mmsm

View on

11 Feb 2023

CONGRESS | #CART23
Roman Hajek presents access to CAR-T on a global scale - Central and Eastern Europe. Discrepancies exist in the availability and reimbursement of CAR-T product cost across the region. Access to clinical trials represents a key challenge for patients. #mmsm

View on

11 Feb 2023

CONGRESS | #CART23
@i_yakoub_agha presents updates to European guidelines on CAR T-cell therapy toxicity management, including EBMT/EHA recommendations.
#mmsm #medicalcongress #hematology

View on

10 Feb 2023

CONGRESS | #CART23
@fdezdelarrea @hospitalclinic presents data on the humanized anti-BCMA CAR-T therapy ARIcel in patients with #MM. The results show encouraging efficacy with an acceptable safety profile.
#mmsm #medicalcongress

View on

10 Feb 2023

CONGRESS | #CART23
Dr. Philippe Moreau discusses biomarkers, PK, and risk factors in relation to CAR T-cell therapy in #MM, illustrated with data from the KarMMa trial as well as real world data. Dose and prior BCMA exposure are important factors in disease outcome. #mmsm

View on

10 Feb 2023

CONGRESS | #CART23 @H_Einsele @Uni_WUE gives an overview of CAR-T in #MM, discussing key trials, treatment strategies and novel targets. Combination therapies may further improve MM outcomes, with CAR-T potentially becoming part of first-line therapy for high-risk pts #mmsm

View on

9 Feb 2023

CONGRESS | #CART23 Vladan Vucinic presents a longitudinal single-cell multi-omic analysis of cells collected at lymphapheresis, detecting factors associated with CR after anti-BCMA CAR T-cell therapy. Immunocompetence of the host immune system is essential for achieving CR. #mmsm

View on

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

CAR-T 2023 EHA–EBMT European CAR T-Cell Meeting

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Subscribe to get the best content delivered to your inbox

CAR-T 2023

Newsletter